Global Organ-based/Targeted Drug Delivery Devices Market for Biologics 2020 - 2030 -

DUBLIN--()--The "Organ-based/Targeted Drug Delivery Devices Market for Biologics (Intra-organ / Intra-tumoral), 2020 - 2030" report has been added to's offering.

Over the years, advances in cell biology and pharmacology have led to the development of a variety of advanced biologics, which experts believe, possess the potential to address several unmet needs associated with the treatment of different types of diseases. Currently, there are more than 1,000 cell and gene therapies under development; most of which are being developed for the treatment of oncological disorders, cardiovascular disorders and neurological disorders. Additionally, over the last decade, multiple immunotherapies have been developed, and have led to a decrease in lung cancer and melanoma-related mortality. Despite their many benefits, biologics present a number of challenges, such as drug delivery related complexities, and immunogenicity concerns, which have been shown to result in systemic toxicity post therapy administration. To avoid such systemic toxic effects, a limited volume of drug is administered, which often results in a small amount of drug reaching the target organ. Further, from a pharmacological point of view, the drug stays at the target site for a limited time, hence decreasing the final therapeutic effect that can be achieved through prolonged and controlled drug delivery. Moreover, some of such treatment options, such as cell therapies, require periodic administration of additional therapy material, or complementary products, thereby, adding to the already complex invasive dosing procedure.

In order to address challenges, a number of innovator companies in the biopharmaceutical sector are actively engaged in identifying targeted and effective delivery strategies for biologics, including gene therapies, cell/stem cell therapies, immunotherapies and therapeutic proteins. Examples of devices designed for the targeted delivery of biologics include Advance CS, ExtroducerTM microcatheter, HelixTM biotherapeutic delivery system, ImmunoPulse IL-12, SmartFlow neuro ventricular cannula and MailPan. Some drug delivery devices have been demonstrated to have an improved therapeutic safety index, and are capable of accurately delivering biological interventions to the target physiological site. Further, certain implantable delivery systems have also been developed in order to prolong the therapeutic effect of biologics. Given the rapid pace of growth within the biopharmaceutical market, the demand for effective delivery systems is anticipated to increase in the foreseen future. This may be expected to create lucrative opportunities for stakeholders in the targeted drug delivery systems market.

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of such medical devices, over the next decade. The study features an in-depth analysis of the key drivers and trends related to this domain.

  • What type of devices are capable of providing targeted delivery of biologics?
  • Who are the leading device developers in this domain?
  • What are the key promising therapeutic areas for the development of targeted drug delivery devices for stem cell and gene therapies?
  • Which companies can be considered as potential strategic partners for device developers?
  • How is the current and future opportunity likely to be distributed across key market segments and geographical regions?

Key Topics Covered:












Companies Mentioned

  • 4D Molecular Therapeutics
  • AbbVie
  • Abeona Therapeutics
  • Advantagene
  • Advaxis
  • Adverum Biotechnologies
  • Alcyone Lifesciences
  • Allergan
  • AlphaVax
  • Altaco XXI
  • Amgen
  • Amicus Therapeutics
  • Anaeropharma Science
  • Anchiano Therapeutics
  • AnGes
  • Angionetics
  • apceth Biopharma
  • Apic Bio
  • AskBio
  • Astellas Pharma
  • Athersys
  • Atrium Medical
  • Austrianova
  • AveXis
  • Axis Biotec Brasil
  • Axovant
  • Azidus Brasil
  • BHI Therapeutic Sciences
  • BioCardia
  • Biogen
  • BioGenCell
  • BioInvent
  • Bioquark
  • BioRestorative Therapies
  • Biosense Webster
  • bluebird bio
  • Boehringer Ingelheim
  • CellProthera
  • Celsion
  • Celyad
  • Cesca Therapeutics
  • Generation Bio
  • Genexine
  • Genprex
  • GenSight Biologics
  • Global Cell Med
  • Gloriana Therapeutics
  • Gradalis
  • IVERIC bio
  • Janssen
  • Japan Regenerative Medicine
  • Japan Tissue Engineering
  • jCyte
  • Jennerex Biotherapeutics
  • Juventas Therapeutics
  • Kadimastem
  • Karolinska Institutet
  • Kolon TissueGene
  • K-Stem Cell
  • Kubota Pharmaceutical
  • Lacerta Therapeutics
  • Lifecells
  • Lineage Cell Therapeutics
  • Living Cell Technologies
  • Lokon Pharma
  • Longeveron
  • Lysogene
  • Marsala Biotech
  • Massachusetts Institute of Technology
  • Med Cell Bahamas
  • MedImmune
  • MeiraGTx
  • Mercator MedSystems
  • Nature Cell
  • Neuracle Genetics
  • Oxford BioMedica
  • Passage Bio
  • Pattern BioScience
  • PeriphaGen
  • Pfizer
  • PharmaCyte Biotech
  • Pharmicell
  • Pluristem Therapeutics
  • Plus Therapeutics
  • Prevail Therapeutics
  • Promethera Biosciences
  • PsiOxus Therapeutics
  • PTC Therapeutics
  • Q Therapeutics
  • Regeneron Pharmaceuticals
  • Reliance Life Sciences
  • ReNeuron
  • Renishaw
  • Renova Therapeutics
  • Riordan Technologies
  • SanBio
  • Sangamo Therapeutics
  • Sanofi
  • Sarepta Therapeutics
  • Scancell
  • Sclnow Biotechnology
  • SCM LifeScience
  • Seneca Biopharma
  • Sentien Biotechnologies
  • Seraxis
  • Shire
  • Sibiono GeneTech
  • Sigilon Therapeutics
  • SillaJen
  • Smartwise
  • Southwest Research Institute
  • Spark Therapeutics
  • Stem Med
  • Stemedica Cell Technologies
  • Steminent Biotherapeutics
  • Stempeutics Research
  • StrideBio
  • SWIB Holding
  • Taiwan Bio Therapeutics
  • Takeda
  • Targovax
  • Tocagen
  • Transgene
  • Translational Research Institute
  • TransVascular
  • Trinity College Dublin
  • U.S. Stem Cell
  • VCN Biosciences
  • Vericel
  • Verve Therapeutics
  • Vessl
  • ViroMed
  • Virttu Biologics
  • Viscofan BioEngineering
  • Voyager Therapeutics
  • XyloCor Therapeutics

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900